Meda License, Development and Supply Agreements (Details) (USD $)	Jun. 30, 2012	Dec. 31, 2011
Summary of contractual rights, obligations and related cash flows
Total Milestones	$ 76,390,290	$ 73,890,290
Release of Milestones upon and subsequent to first sale	(59,834,770)	(59,735,570)
Remaining Deferred Revenue	16,555,520	14,154,720
North America [Member]
Summary of contractual rights, obligations and related cash flows
Total Milestones	61,341,570	61,341,570
North America [Member] | License rights to ONSOLIS (BEMA Fentanyl) [Member]
Summary of contractual rights, obligations and related cash flows
Total Milestones	59,800,000	59,800,000
North America [Member] | Non-cancer subsequent indication of product and further development of initial product [Member]
Summary of contractual rights, obligations and related cash flows
Total Milestones	1,541,570	1,541,570
Europe and Rest of World [Member]
Summary of contractual rights, obligations and related cash flows
Total Milestones	15,048,720	12,548,720
Europe and Rest of World [Member] | License rights to BREAKYL (BEMA Fentanyl) [Member]
Summary of contractual rights, obligations and related cash flows
Total Milestones	10,500,000	8,000,000
Europe and Rest of World [Member] | BREAKYL product through governmental approval in E.U. country [Member]
Summary of contractual rights, obligations and related cash flows
Total Milestones	$ 4,548,720	$ 4,548,720